ReNeuron Group plc (LON:RENE – Get Free Report) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 3.38 ($0.04) and traded as low as GBX 3.28 ($0.04). ReNeuron Group shares last traded at GBX 3.38 ($0.04), with a volume of 177,373 shares.
ReNeuron Group Stock Down 2.2 %
The company has a quick ratio of 2.02, a current ratio of 1.51 and a debt-to-equity ratio of 14.25. The business has a 50-day simple moving average of GBX 3.38 and a 200-day simple moving average of GBX 3.38. The company has a market cap of £1.93 million, a PE ratio of -37.50 and a beta of 0.83.
ReNeuron Group Company Profile
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Further Reading
- Five stocks we like better than ReNeuron Group
- What is MarketRank™? How to Use it
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- Why Invest in High-Yield Dividend Stocks?
- AMD Gains Momentum With AI: Can It Beat Expectations?
- P/E Ratio Calculation: How to Assess Stocks
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
